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By intrasplenic  immunization  we  raised a rat  mAb 
(mAb Vlq; IgG2a,~) with a  potent  neutralizing  activ- 
ity  against  natural  mouse TNF (1 pg/ml mAb Vlq/ 
100 U/ml TNF). mAb V l q  was  used to study  the  role 
of  endogenous TNF in  experimental  peritonitis  in- 
duced by sublethal cecal ligation and puncture. 
mAb V l q  persisted  for  over 5 days  in  the  serum  of 
mice  injected  with 100  pg of the  antibody  and,  there- 
fore, proved useful for in  vivo  experiments. As little 
as 20 pg mAb Vlq/mouse  prevented  lethal  shock  of 
the  animals by 400 pg LPS/mouse.  In sublethal  cecal 
ligation  and  puncture  i.p.  injection  of  mAb V l q  di- 
rectly  and  up to 8 h  after  induction  of  experimental 
peritonitis  lead to death of the  animals  within 1 to 
3 days. The lethal  effect of mAb V l q  was  compen- 
sated by  injection  of  recombinant  mouse TNF. Sim- 
ilar  mAb V l q  effects as in  immunocompetent  mice 
were  shown  in  severe  combined  immune  deficiency 
mice  deficient  of  mature  functional B and T cells. 
Taken  together, these data  suggest  that  during  the 
early phase of peritonitis endogenous TNF may 
stimulate  nonlymphoid cells such as granulocytes, 
macrophages, platelets, and fibroblasts to ingest 
bacteria  and to localize  inflammation,  respectively. 
These  beneficial  effects of TNF may  determine  sur- 
vival.  Thus, our data  may  have  implications  for  the 
therapeutic  management of a beginning  peritonitis. 
Many different  in  vitro  and  in vivo effects of TNF have 
previously been described (1-3). TNF has beneficial as 
well a s  deleterious  effects. In experimental  infections it 
was  shown  that locally, TNF accelerates  elimination of 
pathogens,  enhances  leukocyte  infiltration,  induces  an- 
giogenesis, and improves wound healing. Thus, benefi- 
cial in vivo effects were shown in the cases of  BCG 
(Mycobacterium bouis) (4). listeria (5, 6). and  leishmania 
infections (7). The  deleterious role of TNF was  shown  in 
many  in vivo models. TNF is involved in  cachexia (1) and 
exacerbates  murine  cerebral  malaria (8) and  graft  vs  host 
disease (9). Furthermore, it mediates  shock  induced by 
bacteria  and LPS (10. 11). 
Received for publication July  9.  1990. 
The  costs of publlcation of this article were defrayed in part by the 
Accepted for publication  September 10, 1990. 
payment of page charges. This article must therefore be hereby marked 
aduertisement in accordance with 18 U.S.C. Section 1734 solely to indi- 
cate this  fact. 
schungsgemeinschaft (Kr 776/2-1, 776/2-2) and  the European Commu- 
' This work was  supported in part by grants from the Deutsche For- 
nity (TSD-"31 1 - 0 ) .  
Address correspondence and reprint  requests to Dr. Peter H. Kram- 
Center, Heidelberg. F.R.G. 
mer. Institute for Immunology and Genetics. German  Cancer  Research 
In the  experimental  system of CLP3 (1  2). a model of 
bacterial  sepsis  that  resembles  the  clinical  situation of 
a n  infection with a mixed bacterial flora of intestinal 
origin, pretreatment with LPS or TNF was shown to 
increase  the  survival  rates of the injected animals (1 3, 
14). There  are two  possible  explanations  for  this  effect: 
LPS or TNF pretreatment may induce 1) LPS or TNF 
tolerance  or 2) activation of macrophages  and  infiltration 
of granulocytes  that  help  to  fight  the  infection, e.g.. by 
ingestion of bacteria. To distinguish  between  these pos- 
sibilities and to investigate the  contribution of endoge- 
nous TNF to the recovery  from sepsis, we tested the effect 
of a neutralizing  anti-mouse TNF mAb  in sublethal CLP 
(1  5). A neutralizing  rat mAb against  mouse T cell cyto- 
toxin was raised by intrasplenic immunization of rats 
with  partially  purified  cytotoxin  from T cells.  Injection of 
this mAb i.p. during  the  first 8 h after CLP lead to  death 
of all mAb-treated mice. These experiments show the 
beneficial  effect of endogenous TNF and its requirement 
for recovery  from sublethal CLP. 
MATERIALS AND METHODS 
Animals. DBA/2. C3H/HeN, and C57B1/6 mice were obtained 
from  the  lnstitut  fur  Versuchstierforschung,  Hannover. F.R.G., and 
female  Sprague-Dawley rats  from  Mus-Rattus,  Brunntal. F.R.G. The 
animals were kept under the barrier conditions of the German 
Cancer  Research  Center, Heidelberg. F.R.G. SCID mice, a generous 
gift of W. Schuler  and E. Wagner, Basel Institute of Immunology. 
Basel,  Switzerland,  were  kept  in  filter  top  cages. All SCID mice  were 
tested  for  leakiness by ELISA for  mouse IgG and IgM. Only  animals 
with  serum  levels  less  than 5 p g h l  Ig were  used  in  the  experiments. 
Media. Cells were cultured in RPMl 1640 (GIBCO Laboratories, 
Grand  Island, NY) supplemented  with L-glutamine (2 mM), 50 pg/ml 
gentamycin.  HEPES (5 mM). mercaptoethanol(30 pM). and  10%  heat- 
inactivated FCS. For culture of T cell clone 29  medium  supplemented 
with  2%  C63/26 rIL-2 containing  conditioned  medium (1  6) was  used. 
Cells. The  IL-2-dependent  long  term  mouse T cell clone  29  was 
established by limiting  dilution  cloning  from  activated T cells ( 17). 
L929  is a fibrosarcoma  line  from C3H mice.  C63/26 is a L929  clone 
transfected  with  the  human IL-2 cDNA secreting IL-2 into  the su- 
pernatant  (16). 
act. 8 x lo7 U/mg) were a generous gift from BASF/Knoll AG, 
Reagents. rhuTNF-a (sp. act. 9 X lo6 U/mg) and rmTNF-a, sp. 
Ludwigshafen, F.R.G. rhuTNF-(3 (TNF-P(1ymphotoxin). sp. act. 3 X 
lo7 U/mg) was  kindly provided by  Genentech.  South  San  Francisco. 
CA. The  sp.  act.  were  tested  in  the  L929 TNF bioassay as described 
below. 
described (1  8). Briefly, 30.000 L929  cells  were  added  to serial twofold 
L929 TNF bioassay.  The assay was performed as previously 
dilutions of TNF. The  test  was  performed  in  the  presence of 2 p d m l  
Actinomycin D (Sigma  GmbH,  Munchen. F.R.G.). After 20 h a t  37°C 
and 5% C02 in air at 90% relative  humidity  TNF-mediated  cytopathic 
effects on L929 cells were evaluated microscopically or by crista1 
violet (Sigma  Chemical Co.. St. Louis. MO) staining. 
Cytotoxin  purwication. T cell clone 29  was  induced  with 10 p g  
Con A/ml in 10  ml phenol red free medium (Biochrom KG, Berlin. 
hu.  human; m, mouse: SCID. severe combined immune deficiency: V l q .  
Abbreviations used in this paper: CLP. cecal ligation and puncture: 
lgG2a. K monoclonal rat  anti-mouse TNF-N/T cell cytotoxin antibody. 
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F.R.G.) in cell culture  flasks  (no.  3375, Costar.  Cambridge. MA) under 
serumfree conditions for 20 h a t  37°C and 5% CO, in air  at 90% 
relative  humidity. The  supernatant  was centrifuged at  15,000 X g. 
sterile filtered and precipitated at  80%  ammonium  sulfate  satura- 
tion. The precipitated  material was centrifuged again at  15,000 X g. 
dissolved in  10 mM  NaC1/50  mM Tris/HCl. pH 8, and dialysed against 
this  buffer.  This  buffer  was  also used as the  starting  buffer for anion 
exchange HPLC (Spherogel TSK DEAE-5PW. Beckman, Miinchen. 
F.R.G.). The  material  was applied to  the HPLC column in a volume 
of 10 ml at  a flow rate of 1  ml/min. The column was  washed with 
loading buffer  until  baseline  absorption at 280 nm  was reached. The 
adsorbed material  was eluted using a linear  gradient from 10  to 300 
mM  NaCl in 50 mM Tris/HCl pH8. The 1 -ml fractions were collected. 
The cytotoxin activity in individual fractions  was  measured  using 
the L929 TNF bioassay.  Peak cytotoxin activity was  found  at  150 
mM NaCl. The most  active fractions were pooled. dialysed against 
10 mM NaC1/50 mM Tris/HCl. pH 8, and  concentrated 100-fold in a 
vacuum  concentrator. 
total of 130,000 U of partially purified cytotoxin was applied to 15 
Intrasplenic immunization, fusion. and mAb purijication. A 
mm2 of nitrocellulose (Millipore S.A., Molsheim, France). Cytotoxin- 
coated pieces of nitrocellulose were deposited in the spleen of a 
Sprague-Dawley rat as described by Nilsson et al. (19). After four 
intrasplenic immunizations rat spleen cells were fused with the 
mouse myeloma X63.Ag8.653 (20). Anti-cytotoxin hybridomas were 
selected by testing hybridoma supernatants  for neutralization of the 
cytopathic  effect of cytotoxin in  the L929 TNF bioassay. mAb were 
purified from serumfree hybridoma supernatant using the same 
column and conditions as described in Cytotoxin puriJication. 
Determination of mAb persistence  in mice. DBA/2 mice were 
injected 1.p. with 100 pg purified rat anti-mTNF mAb Vlq. The 
were  used to neutralize  128 U/ml cytotoxin in  the L929 TNF assay. 
injected mice were bled daily  from the tail and  the  serum  dilutions 
Effect of rat anti-mTNF mAb V l q  on LPS-induced shock. To 
determine the lethal dose of LPS 10- to 14-wk-old female DBA/P 
mice were injected 1.p. with 50 to 1000 pg LPS (LPS W Salmonella 
minnesota  9700. Difco Laboratories.  Detroit, Ml). A total of 400 pg 
LPS was determined as the  lethal dose of LPS for  this  strain which 
killed 100% of the mice within 3 to 4  days. Subsequently,  groups of 
four mice were injected i.p. with  different  quantities of mAb Vlq or 
with PES 2 h before 1.p. injection of 400 fig LPS. The mice were 
observed for a t  least 2  wk. 
were anesthetized by i.p. injection of 75 mg/kg Ketanest (Parke. 
Cecal  ligation and puncture.  The 10-  to 14-wk-old C3H/HeN mice 
Davis 81 Company,  Miinchen, F.R.G.) and  16 mg/kg Rompun (Bayer 
AG, Leverkusen. F.R.G.) in 0.2 ml sterile, pyrogen-free saline  (Fre- 
senius AG. Bad Homburg, F.R.G.) (12, 15). The  abdominal  skin of 
the mice was  shaved  and a 0.7-cm midline  incision was made. The 
cecum was exteriorized and filled with  feces by milking stool back 
from the  ascending colon. The cecum was ligated below the ileocecal 
valve and  punctured once with a  0.9 x 40-mm  needle.  Gentle  pres- 
sure  was applied  on the ligated cecum to exteriorize a small  amount 
of feces. The cecum was  then  returned  to  the peritoneal  cavity and 
the incision closed with clamps  and Histoacryl blau tissue glue (B. 
Braun Melsungen AG. Melsungen. F.R.G.). Mice were observed for 
a t  least 2  wk. 
RESULTS 
Specificity of rat  anti-mouse TNF mAb  Vlq.We found 
five hybridomas that produced neutralizing anti-cyto- 
toxin mAb. The mAb Vlq (IgGaa,~) was used for further 
investigation. As  an isotype-matched control antibody we 
used mAb V10.12 from the  same  fusion. Table I shows 
TABLE I 
Specificity of rat  anti-mouse TNF mAb V l q  
mAb V l q  Requlred to 
Source of TNFICytotoxin Neutralize 100 U/ml of 
TNF/Cytotoxln (&/mil" 
Con A induced C12gb cytotoxin 
Mouse rTNF 
LPS-induced  mouse TNF serum 




1 6  
240' 
240' 
a Neutralization was tested in the L929 TNF bioassay. 
100 U/ml a k . 2 5  ng/ml. 
C129 is a mouse T cell  clone  in long term culture. 
20 U/ml. 
'No neutralization was seen with 240 /ml mAb Vlq.  
that mAb Vlq neutralizes cytotoxin contained in the Con 
A-induced supernatant of mouse T cell clone 29 and 
natural TNF-a contained  in  serum from LPS injected mice 
with  equal efficiency. One pg/ml  mAb Vlq  was required 
to  neutralize 100 U/ml  mTNF-a or cytotoxin. Consider- 
ably  higher  quantities of mAb Vlq  (16 pg/ml Vlq per 100 
U/ml rmTNF-a) were required to  neutralize rmTNF.  mAb 
Vlq did not neutralize rhuTNF-a or rhuTNF-8. These 
data show that mAb Vlq neutralized both mouse TNF 
and mouse T cell cytotoxin activity and  that  its  neutral- 
izing titer allowed its  use  in  in vivo experiments. 
Persistence of mAb V l q  in mouse  serum. To deter- 
mine mAb V lq  serum  clearance rates mice were injected 
i.p. with 100 pg purified mAb Vlq.  The mice were bled 2 
h and 1  to 5 days  after injection. The  neutralizing  titer of 
mAb Vlq persisting in mouse serum was then deter- 
mined by testing  the  neutralizing  capacity  on 128 U/ml 
of cytotoxin from mouse T cell clone 29. Figure 1 shows 
that  the titer of mAb Vlq in  the  serum of the injected 
mice declined with time after injection as expected. A 
considerable  neutralizing  titer  (1 :40), however, was  still 
found 5 days  after injection. These  results suggested that 
mAb Vlq is suitable for in vivo experiments even in 
situations  in which a prolonged  TNF neutralizing  capac- 
ity is required. 
Protection of mice from  lethal LPS effects  by mAb 
V l q .  It was  shown previously that polyclonal and mAb 
neutralizing TNF-a protected the  animals from the lethal 
effects observed after injection of LPS into mice (1  1). To 
assess  the potency of mAb Vlq in vivo groups of four 
mice were injected with mAb Vlq  at various  concentra- 
tions  2  h before the injection of a  lethal dose of LPS (400 
pg). Amounts of mAb Vlq as low as 20 pg per mouse 
neutralized the lethal TNF-mediated LPS effects com- 
pletely. Control mice injected with PBS were dead at day 
3 or 4 after LPS injection whereas  all mAb Vlq injected 
mice survived even though they showed symptoms of 
endotoxin shock such as ruffled fur  and  diarrhea.  These 
data supported  our  assumption that mAb Vlq  was  suit- 
able for in vivo experiments  because it had  a potent TNF 
neutralizing  capacity. 
Requirement of TNF for  recouery from CLP. TNF- 
mediated endotoxin shock is a model for the deleterious 
0 1 2 3 5 
d after injection 
i.p. with 100 rg mAb V l q  and bled from the tail vein 2 h.  1. 2. 3, and 5 
Figure 1 .  Persistence of  mAb V l q  in  mouse serum. Mice  were injected 
days after injection. Serum in dilutions was used  to neutralize 128 U/ml 
cytotoxin  from  mouse T cell  clone 29 in the L929 TNF bioassay. 
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effects of a massive  septicemia at later stages of a bac- 
terial infection. To assess  the effect of TNF in a more 
localized protracted  infection  with a mixed bacterial 
flora,  however, we used the  system of cecal  ligation and 
puncture as published by Wichterman et al. (12). To 
generate a peritonitis the cecum of mice was ligated and 
punctured. Most strains of mice  including C3H/HeN mice 
used in  our  experiments  survive  the  ensueing  peritonitis 
that develops after CLP. Previous  experiments by Urbas- 
chek  et  al.  (13)  and  Sheppard  et  al.  (14)  had  shown  that 
the injection of small  quantities of LPS or TNF into  mice 
that had undergone a n  otherwise lethal CLP saved a 
significant  percentage of the  animals from  death.  This 
suggested that TNF had a beneficial  effect  in CLP. Alter- 
natively, this protection  may be the  consequence of in- 
duction of LPS/TNF tolerance. To test whether endoge- 
nous TNF was required  for  survival  from  peritonitis C3H/ 
HeN mice were injected with 100 pg purified mAb Vlq 
after  sublethal CLP. Figure  2  shows  that  in  contrast  to 
mice injected  with either PBS or  isotype-matched  control 
mAb,  mice  injected with  mAb Vlq died between 1 and 3 
days after CLP and mAb Vlq injection. We concluded 
from  these  results  that  endogenous TNF was required  to 
survive the peritonitis after CLP. This  was  further  sup- 
ported by experiments  displayed  in Figure 3 which  show 
that  the deleterious  effect of mAb Vlq  was  compensated 
by i.p. administration of as little as 200  ng rmTNF-a  1  h 
after injection of 100 fig mAb Vlq. To further  determine 
the  time  span  during  which TNF is required  for  survival 
from CLP we injected C3H/HeN mice which  had  under- 
gone  sublethal CLP with 100 fig mAb Vlq at 0 to 16 h 
after CLP. Figure  4 shows  that  all mice  injected with mAb 
Vlq at 0 h  or 8 h after CLP died at approximately  1  to 3 
days after the surgical procedure. In contrast,  three of 
six mice that had received mAb Vlq 16 h after CLP 
survived.  These  results  show  that  the  beneficial  effect o  
TNF for  survival  from CLP-induced peritonitis was ex- 
erted  during  the  first 8 h after  onset of the  experimental 
disease. 
TNF-mediated  recovery  from CLP induced  peritonitis 
is independent of functional  mature  lymphocytes. The 
fact  that TNF was required  for  survival  during  the  first 8 
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nitis is overcome by  administration of rmTNF. After CLP mice  were  either 
F i g u r e 3 .  The deleterious  effects  of  mAb Vlq in CLP-induced perito- 
injected with 100 pg mAb Vlq in 0.2 ml PBS or 0.2 ml PBS alone, 
respectively. After 1 h PBS-injected mice were re-injected with 0.2 ml 
PBS. mAb  Vlq-injected  mice  were  injected  either  with 0.2 ml PBS or with 
200 ng or 1000 ng rmTNF in 0.2 ml.  These  injections  were  repeated 12 h 
after CLP. 
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Figure  4. Requirement  of TNF for  survival from CLP during  the  first 
pg mAb Vlq in 0.2 ml PBS. These injections were repeated 24 h after 
8 h of peritonitis. 0. 8, and 16 h  after CLP mice  were  injected  with 100 
CLP. 
h of peritonitis suggested that rather than inducing a 
response by lymphoid  cells TNF may  affect  nonlymphoid 
cells  in  the  peritoneal  cavity. To support  this  assumption 
SCID mice devoid of mature  functional T and B lympho- 
cytes  were  used  (21).  Figure 5 shows  that injection of 100 
pg mAb Vlq  after CLP of SCID mice was  lethal  in  the 
same way as in  the  experiments depicted in Figure 2, in 
which normal C3H/HeN mice with an intact immune 
system  were  used.  These  data  strongly  suggest  that  the 
beneficial effect of TNF in recovery from CLP-induced 
peritonitis is a n  early  effect  on  nonlymphoid  cells, pos- 
sibly granulocytes  and  macrophages,  platelets,  and  fibro- 
blasts. 
DISCUSSION 
We investigated  whether  endogenous TNF supports  the 
recovery from sublethal peritonitis caused by CLP. To 
this end we raised a neutralizing rat anti-mouse TNF 











0 Conlr mAb 
I 
r I I I = I  1 I I 
0 10 20 30 40 50 60 70 00 
h after CLP 
FLgure 5. Requirement of TNF for recovery of SCID mice from CLP. 
Immediately after CLP 7 SCID mice/group were injected with 100 pg mAb 
Vlq ,  or an isotype-matched control antibody in 0.2 ml PES. These injec- 
tions were repeated 12 h after CLP. 
mAb (Vlq) by intrasplenic  immunization. We showed the 
in vivo efficiency of mAb Vlq by demonstrating that it 
protected mice from LPS-induced shock. Injected with 
mAb Vlq  after  sublethal CLP, however, mice died within 
1  to 3 days  after injection. Kinetic experiments showed 
that endogenous TNF was required for survival of the 
mice during the  first 8 h of peritonitis since even 8 h 
after CLP mAb Vlq injection was  lethal. In addition, the 
effect of mAb Vlq  was obtained  in SCID mice suggesting 
that TNF acted directly on nonlymphoid cells. 
It is difficult to obtain sufficient quantities of pure 
natural cytokines for standard immunization.  Therefore, 
we used the small  quantities of a cytotoxin that we iso- 
lated from the  supernatant of a long term mouse T cell 
clone ((2129) for intrasplenic immunization-a method 
that requires only small quantities of Ag (19). We ob- 
tained five mAb, among  them Vlq,  that neutralized both 
TNF-alcachectin and T cell cytotoxin from (2129. C129 
cytotoxin may be identical to TNF-pllymphotoxin be- 
cause in Northern  blots clone 29 mRNA gives a signal 
with a mouse TNF-@ cDNA probe (a generous gift of N. H. 
Ruddle, Yale University Medical School, New Haven, CT). 
This result  agrees  with the  data of Sheehan  et  al.  (22) 
who also found a hamster mAb that neutralized both 
TNF-a and TNF-P after immunization with rmTNF-a (22). 
To ascertain  the quality of mAb Vlq for in vivo use we 
tested its persistence in the circulation. We showed that 
mAb V 1  q is detectable in mouse serum for at least  5  days 
after injection of 100 fig per animal  and  retains  its  neu- 
tralizing  capacity. It has been shown previously that mAb 
or polyclonal anti-TNF  antibodies protect animals from 
LPS-induced lethal  shock (1 1).  The  same effect was ob- 
served with mAb Vlq  and  20 & purified mAb Vlq per 
mouse were sufficient to protect the  animals from the 
lethal effect of 400 Kg LPS. This  result  demonstrated that 
mAb Vlq  was useful in experiments in which large quan- 
tities of endogenous TNF had  to be neutralized. 
The deleterious role of  TNF has been shown in various 
model systems of bacterial  sepsis  or LPS-induced shock. 
In these  systems  animals were exposed to large quantities 
of LPS or bacteria.  This induced a rapid production of 
high levels of TNF that acted systemically and led to 
shock. In contrast, we chose  sublethal CLP as a model 
for a slowly developing sepsis.  This model that resembles 
the clinical situation of sepsis  in  intraabdominal trauma 
enabled us to test  whether endogenous TNF also  exerts 
supportive effects during recovery from sepsis. CLP is 
lethal or sublethal  depending on the mouse strain,  the 
number of cecal punctures made, and  the hygiene state 
of the mice. The  sublethal CLP model has previously been 
used by Moss et  al.  (15) to  show  the  immunosuppressive 
effect of thermal injury. In our  hands, C3H/HeN proved 
to be a  suitable  strain of mice for sublethal CLP. C3H/ 
HeN mice that had received control mAb or PBS after CLP 
did not differ from the mAb Vlq-injected mice in their 
clinical appearance  during  the first 12 h after injection. 
After 12  h, however, in contrast to the control mice, mAb 
Vlq-injected mice started  to die. This result  suggests that 
endogenous TNF is the  essential cytokine for recovery 
from CLP. Further  kinetic  experiments showed that for 
recovery from peritonitis TNF is needed during  the  first 
8 h post CLP. It was shown that the effect was TNF 
specific because the lethal mAb Vlq effect was overcome 
by subsequent injection of 200 ng rmTNF. This result 
suggested an important role for TNF in natural defense 
and prompted us to investigate the effects of TNF in CLP 
of SCID mice  devoid of functional  mature B and T lym- 
phocytes (21). In SCID mice we obtained the  same  data 
as in mice with an intact immune system underlining 
the role of nonlymphoid cells in the peritoneal cavity for 
recovery from CLP. 
Our data do not excIude that early after CLP suboptimal 
amounts of  TNF produced act  on TNF-secreting cells and 
induce a refractory state as found  in early LPS or TNF 
tolerance  (23, 24). However,  we favor other, more direct 
beneficial TNF effects to explain our results. TNF se- 
creted by peritoneal macrophages induced by bacteria 
may further stimulate TNF secretion in an autocrine 
fashion (2). Thus, TNF may stimulate chemotaxis and 
lead to rapid infiltration of neutrophils  into  the peritoneal 
cavity. This may be a consequence of enhanced  adhesion 
of such cells to the vascular endothelium followed by 
increased  diapedesis  (25,261. Complement secreted upon 
TNF stimulation may mediate disruption of capillaries 
and hemorrhagic  necrosis  (27).  Such  disruption of capil- 
laries may prevent rapid spread of bacteria  into the cir- 
culation and  thus prevent  general  septicemia after CLP. 
In addition, TNF may stimulate  the production of acute 
phase  proteins such as  C-reactive protein, complement 
factors, and fibrinogen.  These  proteins play an essential 
role in chemotaxis,  activation of neutrophils,  opsonisa- 
tion of bacteria,  direct  bacteriolysis,  and  abscess  forma- 
tion (28).  Furthermore, TNF may activate procoagulant 
function on the endothelial surface. This in turn may 
lead to  disseminated  intravascular coagulation. In addi- 
tion, TNF may inhibit fibrinolysis by transcriptional 
induction of plasminogen activator  inhibitors and sup- 
pression of tissue-type plasminogen activator  (29).  The 
combination of activation of procoagulant activity, 
fibrinogen, and  fibrin formation, and  the inhibition of 
fibrinolysis may stabilize  fibrin at  the  site of inflamma- 
tion in the peritoneum.  Stability of fibrin clots in  abscess 
formation may further come from the ability of TNF to 
stimulate  fibroblast growth and collagen production (30). 
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In conclusion, therefore, our data show a beneficial 
early role for TNF in recovery from peritonitis that may 
have implications for the therapeutic management of 
such a  disease. 
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